BUZZ-Dexcom rises as FDA clears use of its 15-day continuous glucose monitor
Shares of Dexcomrose 8.6% to $72.60 in premarket trading after the U.S. FDA approved its 15-day continuous glucose monitor, the Dexcom G7. This device is designed for adults with diabetes, offering easier glucose management with fewer sensors and less waste. The approval is expected to drive momentum for the company through 2025, according to brokerage William Blair. Prior to this, the stock had declined 14.1% year-to-date.
Shares of medical device maker Dexcom (DXCM.O) rise 8.6% to $72.60 premarket
Co says U.S. FDA has cleared its 15-day continuous glucose monitoring (CGM) device called Dexcom G7 15 Day for people over the age of 18 with diabetes in the United States
Co says the CGM lasts for 15.5 days and helps in “easier glucose management with fewer monthly sensors and reduced monthly waste”
Co’s other G7 CGM lasts for up to 10 days, while its over-the-counter CGM Stelo also lasts for 15 days Approval for co’s 15-day CGM should provide momentum through 2025, brokerage William Blair had said in a note in February
Up to last close, stock had fallen 14.1% YTD
